TP53 and rectal cancer: A meta-analysis of 30 studies highlighted a correlation between wild-type TP53 status and good response to CRT in 1830 rectal cancer patients with risk ratios (RR) of 1.30 (p < 0.001), 1.65 (p = 0.003), and 0.85 (p = 0.